Literature DB >> 12913398

Pharmacologic reperfusion therapy for acute myocardial infarction.

Harry C Lowe1, Briain D Mac Neill, Frans Van de Werf, Ik-Kyung Jang.   

Abstract

Acute myocardial infarction (MI) remains a significant problem in terms of morbidity, mortality and healthcare costs. Pharmacologic reperfusion therapies for MI are becoming increasingly complex. This review therefore places contemporary pharmacologic MI developments into perspective. An historical overview of pharmacologic reperfusion therapy for MI is provided, followed by an analysis of current limitations, treatment options, and present and likely future pharmacologic therapies. Adjunctive percutaneous and other treatments are also discussed, to clarify what is becoming a rapidly changing field.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12913398     DOI： 10.1023/a:1025050208649

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  143 in total

1.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

Authors:  E J Topol
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

2.  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.

Authors: 
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

3.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

4.  Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi.

Authors:  M J Davies; N Woolf; W B Robertson
Journal:  Br Heart J       Date:  1976-07

5.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

6.  Significant atheromatous debris following uncomplicated vein graft direct stenting: evidence supporting routine use of distal protection devices.

Authors:  Harry C Lowe; S L Houser; T Aretz; B D MacNeill; S N Oesterle; I F Palacios
Journal:  J Invasive Cardiol       Date:  2002-10       Impact factor: 2.022

7.  Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies.

Authors:  A Vogt; R von Essen; U Tebbe; W Feuerer; K F Appel; K L Neuhaus
Journal:  J Am Coll Cardiol       Date:  1993-05       Impact factor: 24.094

8.  Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

9.  Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.

Authors:  J H Gurwitz; J M Gore; R J Goldberg; H V Barron; T Breen; A C Rundle; M A Sloan; W French; W J Rogers
Journal:  Ann Intern Med       Date:  1998-10-15       Impact factor: 25.391

10.  Prediction of short- and intermediate-term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization.

Authors:  T Sakuma; Y Hayashi; K Sumii; M Imazu; M Yamakido
Journal:  J Am Coll Cardiol       Date:  1998-10       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.